Envoy Medical, Inc. priced its initial public offering at $0.40 a share, to list on the Nasdaq Capital Market under the symbol COCH. It filed a Form S-1 registration statement for an initial public offering on October 17, 2025. As of November 6, 2026, its final prospectus is on file (Form 424B4, February 12, 2026).
Sell to companies like Envoy Medical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Envoy Medical, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-10-17. It has amended it 3 times. It filed its final prospectus on 2026-02-12, at a public offering price of $0.40 per share. Each fact below is quoted from the filing named with it.
Also on the record for Envoy Medical, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 14, 2026 | Stake report, Schedule 13G/A, by Alta Partners LLC | 2.6% of the class | 5%+ stakes | Source |
| August 27, 2026 | Leadership change: Robert Potashnick appointed, Chief Accounting Officer | — | Leadership changes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G, by Bleichroeder LP | 9.99% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13G/A, by Ayrton Capital LLC | 3.1% of the class | 5%+ stakes | Source |
| April 21, 2026 | Leadership change: Charles S. McKhann appointed, Director | — | Leadership changes | Source |
| February 17, 2026 | Stake report, Schedule 13D/A, by Glen A. Taylor | 84.8% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G, by Ayrton Capital LLC | 7.87% of the class | 5%+ stakes | Source |
| December 8, 2025 | Stake report, Schedule 13D, by Glen A. Taylor | 44.2% of the class | 5%+ stakes | Source |
| August 21, 2025 | Stake report, Schedule 13G, by Alta Partners LLC | 8.3% of the class | 5%+ stakes | Source |
Check before you invest in Envoy Medical, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Envoy Medical, Inc. and the records around it.
Envoy Medical, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Bleichroeder LP also filed stake reports on 16 other companies: MDxHealth SA (Oct 2026), Identiv, Inc. (INVE) (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026)
- Alta Partners LLC also filed stake reports on 26 other companies: Robin Energy Ltd. (Oct 2026), Huachen AI Parking Management Technology Holding Co., Ltd (Oct 2026), C3is Inc. (Oct 2026)
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
Also filing to list on the Nasdaq Capital Market
IPO filings on the Nasdaq Capital Market in Q1 2026, newest first.
- FARLONG HOLDING Corp (Mar 2026)
- Innovation Beverage Group Ltd (Mar 2026)
Watch Envoy Medical, Inc.
Get an email when Envoy Medical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Envoy Medical, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Envoy Medical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Envoy Medical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our Common Stock is listed on The Nasdaq Capital Market under the symbol “COCH” and our Public Warrants are listed on The Nasdaq Capital Market under the symbol “COCHW.” On February 10, 2026, the closing price of our Common Stock was $0.39 per share and the closing price for our Public Warrants was $0.036 per warrant.From the 424B4 filed 2026-02-12
Shares offered
We are offering on a reasonable best efforts basis 47,946,150 shares of our Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), together with Series A-1 warrants to purchase up to 45,000,000 shares of Common Stock (“ Series A-1 Warrants ”), and Series A-2 warrants to purchase up to 75,000,000 shares of Common Stock (“ Series A-2 Warrants ” and collectively with the Series A-1 Warrants, the “ Common Warrants ”).From the 424B4 filed 2026-02-12
Offering price
After giving effect to the shares of our Common Stock to be sold in this offering at a public offering price of $0.40 per share, our as adjusted net tangible book value as of September 30, 2025 would have been $20.2 million, or approximately $0.28 per share of our Common Stock.From the 424B4 filed 2026-02-12
Use of proceeds
Our management will have broad discretion in the application of the net proceeds, including for any of the purposes described in the section of this prospectus entitled “ Use of Proceeds .” We currently intend to use the net proceeds from this offering for working capital and general corporate purposes.From the 424B4 filed 2026-02-12
Net loss or income
We had net losses of $17.2 million and $16.2 million for the nine months ended September 30, 2025 and 2024, respectively, and had an accumulated deficit of $305.7 million and $284.7 million as of September 30, 2025 and December 31, 2024, respectively.From the S-1/A filed 2026-02-06
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-10-17 | Registration statement filed | S-1 |
| 2025-12-01 | Registration statement amended | S-1/A |
| 2025-12-18 | Registration statement filed | S-1 |
| 2026-02-06 | Registration statement amended | S-1/A |
| 2026-02-10 | Registration statement amended | S-1/A |
| 2026-02-12 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-02-12 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Envoy Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.